中国临床药理学与治疗学2016，Vol.21Issue(5)：579-585,7.
组蛋白去乙酰化酶抑制剂联合用药研究进展
Research advances on histone deacetylase inhibitor combination therapy
摘要
Abstract
HDACi is a new developed class of anticancer drugs which can play a role of anti-tumor by adjusting the nucleosome structure to control the expression of the tumor suppressor gene.Recently,the reported compounds which inhibit HDACs activities were fewer and fewer.The reports about the HDACi combined with other antitumor drugs that aimed at the other target points had been increased gradually.This work introduced the antitumor mechanism and achievements of HDACi in combination with the cytotoxic drugs,ATRA,DNMT-Ⅰ,proteasome inhibitor,DNA repair inhibitors,proteasome inhibitors,etc.The expectation about the research and development of the antineoplastic drugs was also been made in this paper.关键词
组蛋白乙酰酶抑制剂/联合治疗/抗肿瘤Key words
histone acetylase inhibitors/combined therapy/antitumor分类
医药卫生引用本文复制引用
吕子强,吕紫阳,马成华,马晓成,马小罕,涂志..组蛋白去乙酰化酶抑制剂联合用药研究进展[J].中国临床药理学与治疗学,2016,21(5):579-585,7.基金项目
国家科技支撑计划课题(2011BAI05B05) （2011BAI05B05）
